CO2022002616A2 - Composiciones de trofinetida - Google Patents
Composiciones de trofinetidaInfo
- Publication number
- CO2022002616A2 CO2022002616A2 CONC2022/0002616A CO2022002616A CO2022002616A2 CO 2022002616 A2 CO2022002616 A2 CO 2022002616A2 CO 2022002616 A CO2022002616 A CO 2022002616A CO 2022002616 A2 CO2022002616 A2 CO 2022002616A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- compounds
- trofinetide
- products
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- BUSXWGRAOZQTEY-SDBXPKJASA-N trofinetide Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@]1(C)CCCN1C(=O)CN BUSXWGRAOZQTEY-SDBXPKJASA-N 0.000 title abstract 2
- 229950005756 trofinetide Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229930000044 secondary metabolite Natural products 0.000 abstract 1
- 238000006884 silylation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/18—Carbon
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882998P | 2019-08-05 | 2019-08-05 | |
| PCT/US2020/044733 WO2021026066A1 (en) | 2019-08-05 | 2020-08-03 | Compositions of trofinetide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022002616A2 true CO2022002616A2 (es) | 2022-06-10 |
Family
ID=74502416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0002616A CO2022002616A2 (es) | 2019-08-05 | 2022-03-04 | Composiciones de trofinetida |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11370755B2 (https=) |
| EP (1) | EP4009962A4 (https=) |
| JP (2) | JP2022543391A (https=) |
| KR (1) | KR20220059479A (https=) |
| CN (1) | CN114667136A (https=) |
| AU (1) | AU2020324396B2 (https=) |
| BR (1) | BR112022002229A2 (https=) |
| CA (1) | CA3149633A1 (https=) |
| CL (1) | CL2022000301A1 (https=) |
| CO (1) | CO2022002616A2 (https=) |
| IL (1) | IL290324A (https=) |
| JO (1) | JOP20220027A1 (https=) |
| MX (1) | MX2022001505A (https=) |
| MY (1) | MY206115A (https=) |
| SA (1) | SA522431585B1 (https=) |
| WO (1) | WO2021026066A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| MX2023014655A (es) * | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2025169163A1 (en) * | 2024-02-10 | 2025-08-14 | Teadus Pharma Private Limited | Method for the synthesis of trofinetide and its analogues |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573765B1 (fr) * | 1984-11-23 | 1988-06-10 | Solvay | Procede pour la synthese de peptides |
| US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| EP1888618A4 (en) * | 2005-05-23 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Analogs of glycyl-prolyl-glutamate |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| EP2060580A1 (en) * | 2007-11-19 | 2009-05-20 | SOLVAY (Société Anonyme) | Process for the manufacture of persilylated peptides |
| AU2012209466C1 (en) * | 2011-01-27 | 2016-06-23 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
-
2020
- 2020-08-03 KR KR1020227006982A patent/KR20220059479A/ko active Pending
- 2020-08-03 MX MX2022001505A patent/MX2022001505A/es unknown
- 2020-08-03 EP EP20850753.3A patent/EP4009962A4/en active Pending
- 2020-08-03 WO PCT/US2020/044733 patent/WO2021026066A1/en not_active Ceased
- 2020-08-03 MY MYPI2022000626A patent/MY206115A/en unknown
- 2020-08-03 CA CA3149633A patent/CA3149633A1/en active Pending
- 2020-08-03 BR BR112022002229A patent/BR112022002229A2/pt unknown
- 2020-08-03 AU AU2020324396A patent/AU2020324396B2/en active Active
- 2020-08-03 CN CN202080062340.0A patent/CN114667136A/zh active Pending
- 2020-08-03 JP JP2022506639A patent/JP2022543391A/ja not_active Withdrawn
-
2021
- 2021-06-14 US US17/347,135 patent/US11370755B2/en active Active
-
2022
- 2022-02-01 JO JOP/2022/0027A patent/JOP20220027A1/ar unknown
- 2022-02-03 SA SA522431585A patent/SA522431585B1/ar unknown
- 2022-02-03 IL IL290324A patent/IL290324A/en unknown
- 2022-02-04 CL CL2022000301A patent/CL2022000301A1/es unknown
- 2022-03-04 CO CONC2022/0002616A patent/CO2022002616A2/es unknown
- 2022-06-23 US US17/847,736 patent/US11866406B2/en active Active
-
2023
- 2023-11-21 US US18/516,604 patent/US12297172B2/en active Active
-
2026
- 2026-01-13 JP JP2026003598A patent/JP2026063085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY206115A (en) | 2024-11-29 |
| US12297172B2 (en) | 2025-05-13 |
| CA3149633A1 (en) | 2021-02-11 |
| EP4009962A1 (en) | 2022-06-15 |
| JP2022543391A (ja) | 2022-10-12 |
| US11866406B2 (en) | 2024-01-09 |
| MX2022001505A (es) | 2022-03-11 |
| US20240109841A1 (en) | 2024-04-04 |
| KR20220059479A (ko) | 2022-05-10 |
| EP4009962A4 (en) | 2023-08-09 |
| US20220324799A1 (en) | 2022-10-13 |
| CL2022000301A1 (es) | 2022-09-20 |
| JP2026063085A (ja) | 2026-04-10 |
| BR112022002229A2 (pt) | 2022-04-19 |
| SA522431585B1 (ar) | 2025-02-13 |
| AU2020324396B2 (en) | 2025-07-03 |
| US20220055987A1 (en) | 2022-02-24 |
| AU2020324396A1 (en) | 2022-03-10 |
| IL290324A (en) | 2022-04-01 |
| JOP20220027A1 (ar) | 2023-01-30 |
| CN114667136A (zh) | 2022-06-24 |
| US11370755B2 (en) | 2022-06-28 |
| WO2021026066A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CO2022002616A2 (es) | Composiciones de trofinetida | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| CO2021006672A2 (es) | Moduladores de nlrp3 | |
| UY36530A (es) | Métodos para purificar cannabinoides, composiciones y kits de estos | |
| BR112018014015A2 (pt) | derivados de tioidantoína substituídos como antagonistas do receptor de androgênio | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| CR20140411A (es) | Compuestos de indol e indazol que activan la ampk | |
| BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
| CL2020002275A1 (es) | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y. | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| CL2019002079A1 (es) | Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611) | |
| BR112021018456A2 (pt) | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento | |
| NI202100020A (es) | Inhibidores de pde4 que contienen boro | |
| CL2018003377A1 (es) | Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187) | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| JOP20210332A1 (ar) | عقاقير أولية لمعدلات المستقبل nmda | |
| ECSP22003596A (es) | Moduladores del receptor de nmda | |
| AR130483A1 (es) | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) | |
| BR112018076443A2 (pt) | formas cristalinas de um composto de triazolopirimidina |